BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 27411269)

  • 41. Relationship between fluoride exposure and osteoclast markers during RANKL-induced osteoclast differentiation.
    Junrui P; Bingyun L; Yanhui G; Xu J; Darko GM; Dianjun S
    Environ Toxicol Pharmacol; 2016 Sep; 46():241-245. PubMed ID: 27500448
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression.
    Shevde NK; Bendixen AC; Dienger KM; Pike JW
    Proc Natl Acad Sci U S A; 2000 Jul; 97(14):7829-34. PubMed ID: 10869427
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nrf2 deficiency induces oxidative stress and promotes RANKL-induced osteoclast differentiation.
    Hyeon S; Lee H; Yang Y; Jeong W
    Free Radic Biol Med; 2013 Dec; 65():789-799. PubMed ID: 23954472
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
    Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
    Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Increased osteoclast formation and activity by peripheral blood mononuclear cells in chronic liver disease patients with osteopenia.
    Olivier BJ; Schoenmaker T; Mebius RE; Everts V; Mulder CJ; van Nieuwkerk KM; de Vries TJ; van der Merwe SW
    Hepatology; 2008 Jan; 47(1):259-67. PubMed ID: 18022900
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neogambogic Acid Suppresses Receptor Activator of Nuclear Factor κB Ligand (RANKL)-Induced Osteoclastogenesis by Inhibiting the JNK and NF-κB Pathways in Mouse Bone Marrow-Derived Monocyte/Macrophages.
    Jin G; Wang FF; Li T; Jia DD; Shen Y; Xu HC
    Med Sci Monit; 2018 Apr; 24():2569-2577. PubMed ID: 29698379
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Ascorbic acid inhibits the formation and function of osteoclasts from RAW264.7 cells induced by receptor activated nuclear factor kappaB ligand in vitro].
    Xiao XH; Zhou HD; Yuan LQ; Xie H; Liao EY
    Zhonghua Yi Xue Za Zhi; 2004 Dec; 84(24):2102-6. PubMed ID: 15730627
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Blocking of the Ubiquitin-Proteasome System Prevents Inflammation-Induced Bone Loss by Accelerating M-CSF Receptor c-Fms Degradation in Osteoclast Differentiation.
    Lee K; Kim MY; Ahn H; Kim HS; Shin HI; Jeong D
    Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28946669
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intravenously delivered glucocorticoid liposomes inhibit osteoclast activity and bone erosion in murine antigen-induced arthritis.
    Hofkens W; Grevers LC; Walgreen B; de Vries TJ; Leenen PJ; Everts V; Storm G; van den Berg WB; van Lent PL
    J Control Release; 2011 Jun; 152(3):363-9. PubMed ID: 21396411
    [TBL] [Abstract][Full Text] [Related]  

  • 50. NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis.
    Xing L; Bushnell TP; Carlson L; Tai Z; Tondravi M; Siebenlist U; Young F; Boyce BF
    J Bone Miner Res; 2002 Jul; 17(7):1200-10. PubMed ID: 12096833
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The prenyl group contributes to activities of phytoestrogen 8-prenynaringenin in enhancing bone formation and inhibiting bone resorption in vitro.
    Ming LG; Lv X; Ma XN; Ge BF; Zhen P; Song P; Zhou J; Ma HP; Xian CJ; Chen KM
    Endocrinology; 2013 Mar; 154(3):1202-14. PubMed ID: 23389955
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ebselen Is a Potential Anti-Osteoporosis Agent by Suppressing Receptor Activator of Nuclear Factor Kappa-B Ligand-Induced Osteoclast Differentiation In vitro and Lipopolysaccharide-Induced Inflammatory Bone Destruction In vivo.
    Baek JM; Kim JY; Yoon KH; Oh J; Lee MS
    Int J Biol Sci; 2016; 12(5):478-88. PubMed ID: 27019631
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro.
    Quinn JM; Elliott J; Gillespie MT; Martin TJ
    Endocrinology; 1998 Oct; 139(10):4424-7. PubMed ID: 9751528
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Technetium-99 conjugated with methylene diphosphonate inhibits receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis.
    Gong W; Dou H; Liu X; Sun L; Hou Y
    Clin Exp Pharmacol Physiol; 2012 Oct; 39(10):886-93. PubMed ID: 23013134
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Suppression of osteoclastogenesis by N,N-dimethyl-D-erythro-sphingosine: a sphingosine kinase inhibition-independent action.
    Kim HJ; Lee Y; Chang EJ; Kim HM; Hong SP; Lee ZH; Ryu J; Kim HH
    Mol Pharmacol; 2007 Aug; 72(2):418-28. PubMed ID: 17504945
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells.
    Mancino AT; Klimberg VS; Yamamoto M; Manolagas SC; Abe E
    J Surg Res; 2001 Sep; 100(1):18-24. PubMed ID: 11516200
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lipopolysaccharide from Prevotella nigrescens stimulates osteoclastogenesis in cocultures of bone marrow mononuclear cells and primary osteoblasts.
    Chung YH; Chang EJ; Kim SJ; Kim HH; Kim HM; Lee SB; Ko JS
    J Periodontal Res; 2006 Aug; 41(4):288-96. PubMed ID: 16827722
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Estradiol rapidly inhibits osteoclastogenesis and RANKL expression in bone marrow cultures in postmenopausal women: a pilot study.
    Taxel P; Kaneko H; Lee SK; Aguila HL; Raisz LG; Lorenzo JA
    Osteoporos Int; 2008 Feb; 19(2):193-9. PubMed ID: 17768586
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Limited rescue of osteoclast-poor osteopetrosis after successful engraftment by cord blood from an unrelated donor.
    Nicholls BM; Bredius RG; Hamdy NA; Gerritsen EJ; Lankester AC; Hogendoorn PC; Nesbitt SA; Horton MA; Flanagan AM
    J Bone Miner Res; 2005 Dec; 20(12):2264-70. PubMed ID: 16294279
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Disease status in autosomal dominant osteopetrosis type 2 is determined by osteoclastic properties.
    Chu K; Snyder R; Econs MJ
    J Bone Miner Res; 2006 Jul; 21(7):1089-97. PubMed ID: 16813529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.